vTv Therapeutics Inc. (VTVT)
| Market Cap | 62.74M |
| Revenue (ttm) | 1.02M |
| Net Income (ttm) | -18.46M |
| Shares Out | 3.19M |
| EPS (ttm) | -3.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,843 |
| Open | 19.50 |
| Previous Close | 19.70 |
| Day's Range | 19.50 - 19.50 |
| 52-Week Range | 12.12 - 29.19 |
| Beta | 0.81 |
| Analysts | Strong Buy |
| Price Target | 35.50 (+80.48%) |
| Earnings Date | May 8, 2025 |
About VTVT
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cyst... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VTVT stock is "Strong Buy." The 12-month stock price forecast is $35.5, which is an increase of 80.48% from the latest price.
News
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo...
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges
On Monday, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on vTv Therapeutics Inc.'s VTVT cadisegliatin clinical program.
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati...
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening m...
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in dia...
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global li...
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead progr...
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening m...
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for t...
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly diag...
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insuli...
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunct...
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunct...
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024 Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
WESTON, Fla. , Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening ...
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti...
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti...
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti...
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti...
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19
WESTON, Fla. and ANN ARBOR, Mich.
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
Initiation of Clinical Study at Allegheny Health Network Seeks to Provide Treatment Options to Pancreatic Cancer Patients WESTON, Fla. and PITTSBURGH , Sept.
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
Initiation of Clinical Study at Lenox Hill Hospital Seeks to Provide New Option for Treatment of Newly Diagnosed Unmethylated Glioblastoma WESTON, Fla. and NEW YORK , Sept.
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunct...
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
Cantex's once daily, orally administered, azeliragon inhibits interactions of the receptor for advanced glycation end products (RAGE) Researchers showed RAGE inhibition to be a potential target for tr...